TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04031170

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incredible Years® School Age Basic Parent Training Program
Description: The Incredible Years® School Age Basic Parent Training Program targets many of the proposed mechanisms and risk factors for internalizing distress in early childhood: harsh and unpredictable or critical parenting behaviors. Parents also learn cognitive strategies for themselves; such as self-praise, coping thoughts, how to challenge negative thoughts, and how to get support that they are encouraged to model for and teach their children. Finally, they learn how to be more positive and nurturing through academic, social and emotional coaching.

Intervention type: OTHER
Group type: OTHER
Intervention: American Academy of Pediatrics, Bright Futures Handouts
Description: Written materials that include age-group specific tips on how parents can support their child's development and social and academic success.
Study: NCT00516646

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALT-711
Description: 200 mg bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: bid
Study: NCT02737137

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Manual measurement
Description: Monitoring by ultrasound, Neurostimulation and Measurement Manual of the injection pressure of the local anesthetic

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Measurement with a gauge
Description: Monitoring by ultrasound, Neurostimulation and measurement with a gauge of the pressure of injection of the local anesthetic
Study: NCT03502798

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: scanning a/LCI
Description: Imaging of the cervical epithelium using the scanning a/LCI device.
Study: NCT04186156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KA2507
Description: KA2507, an orally-active new chemical entity, is a potent and selective inhibitor of the HDAC6 enzyme, with potential clinical utility in the treatment of melanoma and other solid tumors. KA2507 has been shown to display potent in vitro activity in a range of cancer cell lines, including melanoma cell lines. KA2507 exerts potent in vivo efficacy in a syngeneic model of B16 melanoma. Here, the combination of the agent's direct tumor growth inhibition and metastasis suppression, coupled with its immunotherapeutic activity - demonstrated by decreased expression of STAT-3 and PD-L1 and increased expression of acetylated tubulin, gp100 and MHC Class I in tumors - have been observed.
Study: NCT02640560

Intervention type: OTHER
Intervention: Food allergy questionnaire
Description: The Parents of the cases children will compile a questionnaire including questions about general information on the family, on life and food habits, on indoor environment, on health status, on clinical aspects of the allergy, on the access to diagnostic and treatment resources

Intervention type: OTHER
Intervention: Control Questionnaire
Description: The Parents of the control children will compile a questionnaire including questions about general information on the family, on life and food habits and on indoor environment.
Study: NCT01344564

Intervention type: DRUG
Group type: OTHER
Intervention: Degarelix acetate, Leuprolide acetate
Description: Degarelix acetate, 1 mo depot for 3 months Leuprolide acetate, 3 mo depot once
Study: NCT02774083

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Feuerstein Program
Description: Mediated learning cognitive enhancement program

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Adler Program
Description: Social and emotional group program
Study: NCT03213717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heavy Casall HIT weight vest
Description: A weight west with a weight of 10 % compared to the study subject

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standing
Description: Study subjects will be standing for at least 50 minutes every hour

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standing
Description: Study subjects will be standing for at least 50 minutes every hour

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water load
Description: Study subjects will drink 5 ml per kg body weight at the start of experiment and continue drinking the same volume as excreted by the kidneys during the experiment

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Water load
Description: Study subjects will drink 5 ml per kg body weight at the start of experiment and continue drinking the same volume as excreted by the kidneys during the experiment

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Water load
Description: Study subjects will drink 5 ml per kg body weight at the start of experiment and continue drinking the same volume as excreted by the kidneys during the experiment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sitting
Description: Study subjects will be sitting for at least 50 minutes of every hour

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Light Casall HIT weight vest
Description: A weight west with a weight of 1 % compared to the study subject

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Light Casall HIT weight vest
Description: A weight west with a weight of 1 % compared to the study subject
Study: NCT04023578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RHEO KNEE XC
Description: Microprocessor controlled knee using Magneto-Rheologic techonology.
Study: NCT01563081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Description: Clear solution, 0.50 mg levocetirizine dihydrochloride contains in one milliliter of the solution. Levocetirizine oral solution are administered once daily at a dose of 2.5 mL (1.25 mg of levocetirizine) in the morning to infants aged between 6 months and 1 year old

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Description: Clear solution, 0.50 mg levocetirizine dihydrochloride contains in one milliliter of the solution. Levocetirizine oral solution are administered twice daily at a dose of 2.5 mL (1.25 mg of levocetirizine) in the morning and evening before sleep to infants aged between 1 year and 2 years old
Study: NCT02171455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate medium dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02141932

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bed-side pocket size ultrasound imaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GE Ultrasound Vscan
Study: NCT03430739

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT01026493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide 60 mg x 21 days
Description: Temozolomide 60 mg/m2 x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide 60 mg x 21 days
Description: Temozolomide 60 mg/m2 x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide 75 mg x 21 days
Description: Temozolomide 75 mg/m2 x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide 75 mg x 21 days
Description: Temozolomide 75 mg/m2 x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide 75 mg x 21 days
Description: Temozolomide 75 mg/m2 x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide 75 mg x 21 days
Description: Temozolomide 75 mg/m2 x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-888 20 mg x 21 days
Description: 20 mg bid x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-888 20 mg x 21 days
Description: 20 mg bid x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-888 40 mg x 21 days
Description: 40 mg bid x 21 days/28-day cycle. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude further therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-888 40 mg x 21 days
Description: 40 mg bid x 21 days/28-day cycle. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude further therapy
Study: NCT03923790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Packet
Description: The patient will receive an educational packet.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Packet
Description: The patient will receive an educational packet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone call at 72 hours by discharge nurse navigator
Description: Patients will receive a phone call at 72 hours by the discharge nurse navigator (standard of care) to assure that they have received their medications and follow-up appointments

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phone call at 72 hours by discharge nurse navigator
Description: Patients will receive a phone call at 72 hours by the discharge nurse navigator (standard of care) to assure that they have received their medications and follow-up appointments

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth visit at 7 days, 1 month, 3 months, and 5 months after discharge
Description: A stroke prevention trained nurse practitioner or MD or social worker will review the participant's hospital records and depression, dietary, and sleep apnea screens,will reinforce the care plan based on patient-specific needs.They will counsel patients on salt reduction, the Mediterranean diet, and the importance of diet and exercise for stroke prevention.Along with the pharmacist they will also review the BP data to determine the need for medication adjustment and will discuss the side effects and interactions.The social worker will assess the need for medication assistance and other resources. The care plan will be shared with primary care providers (PCP)and patients will be referred to a PCP if they do not have one. The social worker will also will assist uninsured patients in applying for Texas County Indigent Care programs.
Study: NCT02239900

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Treatment Group 1 and 3: SBRT 50 Gy in 4 fractions to 1 - 4 liver lesion(s) on Days 1 - 4 of Cycle 1.~Treatment Group 2 and 4: SBRT 50 Gy in 4 fractions to 1-4 liver lesion(s) on Days 29 - 33 of each 21 day cycle.~Treatment Group 5: SBRT 60 Gy in 10 fractions to 1 - 4 lung, liver, or adrenal lesion (s) on Days 1 - 5 and Days 9 - 12 of Cycle 1.
Study: NCT03923790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational messages every other week
Description: The messages will be sent to the participants cellular phones and will contain one of the following: a reminder to monitor BP, information from about lifestyle and diet for BP reduction, or a message from the pharmacist about medication adherence

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: BP monitoring by QardioARM with periodic transmission of BP data
Description: Participants will be prompted to transmit BP logs through the telemonitoring device every 2 weeks until average BP is \< 130/80, then monthly thereafter. Uncontrolled BP will prompt a call from the pharmacist to discuss medication adherence and the need for further titration.
Study: NCT01513408

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemical detection of lymphocytes T CD8+/Foxp3 ratio
Description: For each patients included the study, a tumour block from the initial biopsy, as well as a representative block of residual tumour (area of complete tumoral regression, area of partial tumoral regression or area of unmodified residual tumour) will be chosen by the initial pathologist in each investigating centre. Once the pathologist has verified the concordance between the images observed on the blocks sent from the investigating centres, and the associated pathology reports, immunohistochemical analysis will be performed on the slides prepared from each block.
Study: NCT00215735

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: debridement, dressing, and APC
Description: ebridement, dressing, and APC
Study: NCT03656952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: a single oral dose of 200 mg PF-06700841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: a single oral dose of 200 mg PF-06700841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: a single oral dose of 200 mg PF-06700841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: a single oral dose of 200 mg PF-06700841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: a single oral dose of 200 mg PF-06700841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: a single oral dose of 200 mg PF-06700841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching PF-06700841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching PF-06700841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching PF-06700841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching PF-06700841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching PF-06700841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching PF-06700841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: a single oral dose of 400 mg moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: a single oral dose of 400 mg moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: a single oral dose of 400 mg moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: a single oral dose of 400 mg moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: a single oral dose of 400 mg moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: a single oral dose of 400 mg moxifloxacin
Study: NCT03018444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin tablet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT00567034

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naltrexone
Description: 50mg naltrexone, 1 tablet a day for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: lactose placebo, 1 capsule every day for 12 weeks
Study: NCT01793623

Intervention type: OTHER
Intervention: atrial tissue
Description: retrieval of discarded atrial tissue
Study: NCT02589054

Intervention type: OTHER
Intervention: Monitoring
Study: NCT02408588

Intervention type: OTHER
Intervention: Pulse oximeter
Description: Place a pulse oximeter on the subject which will record the pulse oximeter waveform.

Intervention type: OTHER
Intervention: Pulse oximeter
Description: Place a pulse oximeter on the subject which will record the pulse oximeter waveform.

Intervention type: OTHER
Intervention: Pulse oximeter
Description: Place a pulse oximeter on the subject which will record the pulse oximeter waveform.
Study: NCT04664803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefecin Tab.
Study: NCT02408588

Intervention type: OTHER
Intervention: Pulse oximeter
Description: Place a pulse oximeter on the subject which will record the pulse oximeter waveform.
Study: NCT02398240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Day 1 and 15 Dose: 1.2 mg/kg/dose. (Maximum dose is 120 mg)
Study: NCT04664803

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omnicef Cap.
Study: NCT00926627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosentan
Description: 62.5 mg tablets b.i.d. administered orally for 4 weeks followed by the maintenance dose of 125 mg b.i.d. (62.5 mg b.i.d. if body weight \< 40 kg/90 lb)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: identical preparation as the study drug, but without the active substance, administered b.i.d.
Study: NCT02691117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: garlic concentrate
Description: Topical application of GarlicRich gel on the scalp areas affected with alopecia areata once a day for 6 months
Study: NCT00834327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aplindore MR tablets or Placebo
Description: aplindore MR tablets administered QD for about 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aplindore MR tablets or Placebo
Description: aplindore MR tablets administered QD for about 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aplindore MR tablets or Placebo
Description: aplindore MR tablets administered QD for about 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aplindore MR tablets or Placebo
Description: aplindore MR tablets administered QD for about 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: aplindore MR tablets or Placebo
Description: aplindore MR tablets administered QD for about 4 weeks
Study: NCT00875602

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EverOn (EarlySense) contactless monitoring device
Description: Hospitalized patients on the study unit are monitored by a contactless device
Study: NCT04873739

Intervention type: DIAGNOSTIC_TEST
Intervention: Anterior Segment OCT
Description: AS-OCT for SLE patients with dry eye, SLE patients without dry eye and compare them with normal subjects.

Intervention type: DIAGNOSTIC_TEST
Intervention: Anterior Segment OCT
Description: AS-OCT for SLE patients with dry eye, SLE patients without dry eye and compare them with normal subjects.

Intervention type: DIAGNOSTIC_TEST
Intervention: Anterior Segment OCT
Description: AS-OCT for SLE patients with dry eye, SLE patients without dry eye and compare them with normal subjects.
Study: NCT02883127

Intervention type: BEHAVIORAL
Intervention: Motivational interviewing
Description: The aim is to provide a one-to-one contact every second week of approximately 10 minutes duration. An action plan for improving dietary behavior will be made during the first session and evaluated in subsequent sessions. The following dietary objectives will be set for each participant to achieve or to maintain:~1. Watch portion size - to be conscious about the amount of carbohydrates in each meal.~2. Eat mainly carbohydrates of low glycaemic index.~3. Reduce the intake of carbohydrate of high glycaemic index.~4. Watch daily weight changes - aim for the recommended weekly changes.~In addition to the motivational intervention the women are given unchanged routine care.
Study: NCT01540331

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: model 1000 PNT vacuum controller (the vacuum device for ocular suction)
Description: A Pneumatic Trabeculoplasty treatment, composed of 3 single PNT applications at day 0, 7 and 90. Each treatment consist in a ocular pneumatic suction of 500inchHg administered for 60 seconds in perilimbal region through the device (model 1000 PNT vacuum controller). This suction is then repeated after a 5 minutes pause.
Study: NCT00925132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide, Decitabine, Panobinostat
Description: Temozolomide - given each cycle.~Decitabine - 6 cohorts with dose escalation.~Panobinostat - 6 cohorts with dose escalation.
Study: NCT03748992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gNO
Description: This is a proof-of-concept study in which all subjects will be treated with gNO (i.e. no control) to see if there can be a microbiological effect by conversion to negative sputum cultures and how long that effect can be sustained following treatment.~Participants will be treated for 3 weeks (5 days per week), Monday through Friday, and followed monthly for 3 months.~The treatment period includes a physical exam, vital signs, blood tests, echocardiogram, spirometry test, sputum sample, questionnaires, and the inhalation gas treatment. During the inhalation gas treatment, participants will wear a face mask (similar to an oxygen mask) and will be given nitric oxide gas through the participants nose for three treatments with fifty minutes each time. They will then be followed up monthly during the Follow-up period with tests that include a physical exam and questionnaires.
Study: NCT03450226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: stellate ganglion block
Description: After induction of general anesthesia, patients will receive a stellate ganglion block using a standard and well described paratracheal technique, The patient's head will be extended and a 4-5-cm, 22-gauge needle inserted at the medial edge of the sternocleidomastoid muscle just below the level of the cricoid cartilage at the level of the transverse process of C6 or C7. After advancing to the transverse process the needle will be withdrawn 2-3 mm prior to injection. A negative aspiration test will be performed in two planes before a 1-ml test dose is used to exclude unintentional intravascular injection (vertebral or subclavian arteries) or subarachnoid injection into the dural sleeve.4 A total of 10 ml of 0.25% bupivacaine will be injected.